Company Snapshot
- Ticker
- REGN
- Name
- REGN
- Sector
- None
- Currency
- 0
- Relative Volume
- None
- Market Cap
- 77986174320.559998
- Volume
- 903,156
- Avg Volume (3M)
- 1,067,430
REGN
REGN
Last update recent
752.62
+11.33
(+1.53%)
Market Cap
77986174320.559998
Dividend Yield
0.00%
1Y Return
None%
Beta
None
Price & Moving Averages
Interactive chart with SMA overlays and intraday breadth.
Profitability
- Revenue
- 14247800000.000000
- EPS
- 43.44
- Dividend / Share
- None
- Total Dividends
- $0.00
- Dividend Yield
- 0.36%
- Net Income
- 4578000000.000000
- Net Margin
- 32.13%
- Payout Ratio
- 6.06%
- Qtly Growth YoY
- None
Valuation & Quality
- P/E
- 17.04
- Forward P/E
- None
- P/S
- 5.47
- P/B
- 2.52
- Beta
- None
- Debt / Equity
- 0.09
- Current Ratio
- 4.06
- Return on Equity
- 0.15%
- Return on Assets
- 0.11%
Technicals & Returns
- Distance vs 200 DMA
- 25.82%
- 200 DMA
- 598.15
- Distance vs 50 DMA
- 13.46%
- 50 DMA
- 663.31
- Return 1Y
- None%
- Return YTD
- None%
- Beta (Trailing)
- None
- Relative Volume
- None
Factor Lens
Plot valuation, momentum, or volume trends.
Seasonal Performance
Company Overview
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and Read more
- Name
- REGN
- Industry
- Biotechnology
- CEO
- Dr. Leonard S. Schleifer M.D., Ph.D.
- Employees
- 13,926
- IPO Date
- 1991-04-02
- Phone
- 914 847 7000
- Address
- None
- Website
- https://www.regeneron.com
Dividend Yield
0.00%
TTM Distributions
$0.00
Latest News
Curated headlines from premium sources.
2 Reasons to Buy Regeneron Stock Like There's No Tomorrow
Regeneron is finding ways to deal with the increased competition to one of its key growth drivers. The company is also developing newer medicines that will imp…
Regeneron (REGN) Just Flashed Golden Cross Signal: Do You Buy?
From a technical perspective, Regeneron (REGN) is looking like an interesting pick, as it just reached a key level of support. REGN recently overtook the 20-da…
Calls of the Day: Regeneron, Booking Holdings, General Dynamics and Fiserv
The Investment Committee debate the latest Calls of the Day.
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript
Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial
A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial treatments, potentially allowing …
Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?
Regeneron Pharmaceuticals once again beat consensus EPS and revenue estimates by a wide margin. Moreover, as of September 30, Regeneron had about $2.2 billion …